Abstract
Objective Silver diamine fluoride (SDF) is a non-surgical treatment for the arrest and prevention of dental caries that results in irreversible black staining of dental decay. The objective of this study was to evaluate the impact of SDF treatment on oral health-related quality of life (OHRQoL) relative to a standard package of glass ionomer sealants and atraumatic restorative treatment.
Methods CariedAway is a pragmatic, longitudinal, cluster-randomized non-inferiority trial of non-surgical interventions for caries. Secondary study outcomes included OHRQoL and academic performance. Oral health-related quality of life was measured at each study visit using the Child Oral Health Impact Profile. Change in OHRQoL was assessed using linear regression and non-inferiority was determined using t-tests.
Results Untreated decay at baseline was associated with signifcantly worse ORHQoL and treatment in both groups resulted in incremental improvement. Quality of life in children receiving silver diamine fluoride was non-inferior to those receiving sealants and ART at least six months post-treatment. Additionally, change in OHRQoL did not depend on the severity of baseline decay.
Conclusions ORHQoL is related to untreated dental caries, however no appreciable change was observed following SDF treatment relative to standard preventive therapies.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03442309
Clinical Protocols
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2891-1
Funding Statement
This work was supported in part by an award from the Patient Centered Outcomes Research Institute (#PCS160936724). The content is solely the responsibility of the authors and does not necessarily reflect the official views of the funding organization, New York University, or the NYU College of Dentistry.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the CariedAway clinical trial was obtained from the New York University School of Medicine Institutional Review Board (i17-00578).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email addresses: ryan.ruff{at}nyu.edu (Ryan Richard Ruff), t.barrygodin{at}nyu.edu (Tamarinda J. Barry Godín), topaz.murray{at}nyu.edu (Topaz Murray Small), r.niederman{at}nyu.edu (Richard Niederman)
Data Availability
Data will be available from investigators upon reasonable request at the completion of the trial.